Loading...
0

Autoimmune Disease Therapeutics Market by Drug Class (Anti-Inflammatory, Antihyperglycemics, NSAIDs, Interferons, and Others), Indication (Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, , Inflammatory Bowel Disease and Others) and Sales Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Store): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

LI_195185
Pages: 202
Feb 2019 | 2805 Views
 
Author(s) : Onkar Sumant & Sayali Shinde
Tables: 94
Charts: 44
 

Autoimmune Disease Therapeutics Market Overview:

The global autoimmune disease therapeutics market was valued at $109,833 million in 2017, and is projected to reach $153,320 million by 2025, registering a CAGR of 4.2% from 2018 to 2025. An autoimmune disease causes the immune system to destroy its own body tissue. There are more than 80 different types of autoimmune disorders; however, lupus, multiple sclerosis, IBS, type 1 diabetes, rheumatoid arthritis, psoriasis, and others are the most common form of autoimmune disease. Different types of drugs such as anti-inflammatory, NSAIDs, interferons, immune suppressants, corticosteroids, and others, are approved for the treatment of autoimmune disease.

Increase in incidence of autoimmune disease, surge in adoption of autoimmune disease therapeutics, and growth in R&D activities to develop ideal therapeutics are the key drivers of the global autoimmune disease therapeutics market. Furthermore, technological advancements in screening procedures, wide availability of therapeutics, and strong presence of pipeline drugs such as tocilizumab, baricitinib, certolizumab, secukinumab, etanercept, olokizumab, abatacept, apremilast, PF-06438179, golimumab, ustekinumab, etrolizumab, tofacitinib and others, are expected to further influence the market growth. On the other side, higher cost of advanced therapeutics can hamper the autoimmune disease therapeutics market growth.

Autoimmune Disease Therapeutics Market Segmentation

The global autoimmune disease therapeutics market is segmented based on drug class, indication, sales channel, and region. Based on drug class, the market is classified as anti-inflammatory, antihyperglycemics, NSAIDs, interferons, and others. On the basis of indication rheumatic disease, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and other indications. According to the sales channel, the market is categorized as hospital pharmacy, drug stores & retail pharmacy, and online store. Based on region, the autoimmune disease therapeutics market size is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).

Get more information on this report: Request Sample Pages

Segment review

Based on drug class, the market is classified as anti-inflammatory, antihyperglycemics, NSAIDs, interferons, and others. Anti-inflammatory was the major revenue contributing segment in 2017 and is expected to exhibit dominance during the forecast period owing to increase in demand for anti- inflammatory drugs, launch of newer anti- inflammatory drugs with the supportive reimbursement policies for use of advanced anti- inflammatory drugs in some countries. Moreover, expected launch of pipeline anti-inflammatories such as tocilizumab, certolizumab, secukinumab, etanercept, golimumab and others, is estimated to further influence the market growth.

Anti-inflammatory drugs are preferably used in the treatment of inflammatory bowel disease, osteoarthritis, rheumatoid arthritis, fibromyalgia, systemic lupus erythematosus, gout, juvenile idiopathic arthritis, infectious arthritis, psoriatic arthritis, ankylosing spondylitis, reactive arthritis, scleroderma, polymyalgia rheumatica etc. Rise in incidence of these disease further fuels the market growth.

Presently, Adalimumab, Etanercept, Infliximab, Abatacept, Certolizumab, Golimumab, Ustekinumab, Tocilizumab, Secukinumab and others are widely used in the treatment of different form of autoimmune disease. Wide availability of anti-inflammatory drugs, preferable use of these drugs with favorable reimbursement in some countries contribute to the market growth.

Get more information on this report: Request Sample Pages

Based on indication, the autoimmune disease therapeutics market is classified as rheumatic disease, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and other indications. The rheumatic disease segment held nearly half of the autoimmune disease therapeutics market share in 2017 and is expected to remain dominant during the forecast period due to strong presence of pipeline drugs, surge in prevalence of arthritis, fibromyalgia, systemic lupus erythematosus, gout, scleroderma, polymyalgia rheumatica and others, wide availability of advanced therapeutics for treatment of rheumatic disease, and availability of advanced therapeutics for the treatment of these diseases.

Get more information on this report: Request Sample Pages

Snapshot of Asia-Pacific autoimmune disease therapeutics market

Asia-Pacific presents lucrative growth opportunities for the key players operating in the autoimmune disease therapeutics market owing to large population base, rise in purchasing power, surge in prevalence of autoimmune disease, and increase in demand for advanced autoimmune disease therapeutics. Growth in number of aging population, and increase in early detection of the disease with rise in healthcare expenditure fuel the growth of the autoimmune disease therapeutics market in this region.

Get more information on this report: Request Sample Pages

The key players profiled in this report include Abbott Laboratories, AbbVie Inc., Amgen Inc.,
AstraZeneca plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis AG, Pfizer Inc., UCB S.A.

Key Benefits for Autoimmune Disease Therapeutics Market:

  • The study provides an in-depth analysis of the market along with the current autoimmune disease therapeutics market trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Autoimmune disease therapeutics market forecast is studied from 2018 to 2025.
  • A comprehensive analysis of all the regions is provided to determine the prevailing opportunities.
  • Autoimmune disease therapeutics market size and estimations are based on a comprehensive analysis of the key developments in the autoimmune disease therapeutics industry.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Autoimmune Disease Therapeutics Key Market Segments:

By Drug Class

  • Anti-inflammatory
  • Antihyperglycemics
  • NSAIDs
  • Interferons
  • Others

By Indication

  • Rheumatic Disease
  • Type 1 Diabetes
  • Multiple Sclerosis
  • Inflammatory Bowel Disease
  • Other Indications

By Sales Channel

  • Hospital Pharmacy
  • Drug Store & Retail Pharmacy
  • Online Store

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:    INTRODUCTION

1.1.    Report description
1.2.    Key benefits for stakeholders
1.3.    Key market segments
1.4.    Research methodology

1.4.1.    Secondary research
1.4.2.    Primary research

1.5.    Analyst tools and models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    Key findings of the study
2.2.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope
3.2.    Key findings

3.2.1.    Top investment pockets
3.2.2.    Top winning strategies

3.3.    Market dynamics

3.3.1.    Drivers

3.3.1.1.    Surge in adoption of autoimmune disease therapeutics
3.3.1.2.    Increase in incidence of autoimmune disease
3.3.1.3.    Wide availability of advanced therapeutics

3.3.2.    Restraints

3.3.2.1.    Higher cost associated with advanced autoimmune disease therapeutics

3.3.3.    Opportunity

3.3.3.1.    Growth opportunities in emerging economies
3.3.3.2.    Strong presence of pipeline drugs

3.4.    Top player positioning, 2017

CHAPTER 4:    AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Anti-inflammatory

4.2.1.    Key market trends, growth factors, and opportunities
4.2.2.    Market size and forecast
4.2.3.    Market analysis, by country

4.3.    Antihyperglycemics

4.3.1.    Key market trends, growth factors, and opportunities
4.3.2.    Market size and forecast
4.3.3.    Market analysis, by country

4.4.    NSAIDs

4.4.1.    Key market trends, growth factors, and opportunities
4.4.2.    Market size and forecast
4.4.3.    Market analysis, by country

4.5.    Interferons

4.5.1.    Key market trends, growth factors, and opportunities
4.5.2.    Market size and forecast
4.5.3.    Market analysis, by country

4.6.    Others

4.6.1.    Key market trends, growth factors, and opportunities
4.6.2.    Market size and forecast
4.6.3.    Market analysis, by country

CHAPTER 5:    AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY INDICATION

5.1.    Overview

5.1.1.    Market size and forecast

5.2.    Rheumatic disease

5.2.1.    Key market trends, growth factors, and opportunities
5.2.2.    Market size and forecast
5.2.3.    Market analysis, by country

5.3.    Type 1 Diabetes

5.3.1.    Key market trends, growth factors, and opportunities
5.3.2.    Market size and forecast
5.3.3.    Market analysis, by country

5.4.    Multiple sclerosis

5.4.1.    Key market trends, growth factors, and opportunities
5.4.2.    Market size and forecast
5.4.3.    Market analysis, by country

5.5.    Inflammatory Bowel Disease

5.5.1.    Key market trends, growth factors, and opportunities
5.5.2.    Market size and forecast
5.5.3.    Market analysis, by country

5.6.    Other indications

5.6.1.    Key market trends, growth factors, and opportunities
5.6.2.    Market size and forecast
5.6.3.    Market analysis, by country

CHAPTER 6:    AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY SALES CHANNEL

6.1.    Overview

6.1.1.    Market size and forecast

6.2.    Hospital pharmacy

6.2.1.    Market size and forecast, by region
6.2.2.    Market analysis, by country

6.3.    Online providers

6.3.1.    Market size and forecast, by region
6.3.2.    Market analysis, by country

6.4.    Drug stores & retail pharmacies

6.4.1.    Market size and forecast, by region
6.4.2.    Market analysis, by country

CHAPTER 7:    GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY REGION

7.1.    Overview

7.1.1.    Market size and forecast

7.2.    North America

7.2.1.    Key market trends and opportunities

7.2.1.1.    US

7.2.1.1.1.    Market size and forecast, by Drug Class
7.2.1.1.2.    Market size and forecast, by Indication
7.2.1.1.3.    Market size and forecast, by Sales Channel

7.2.1.2.    Canada

7.2.1.2.1.    Market size and forecast, by Drug Class
7.2.1.2.2.    Market size and forecast, by Indication
7.2.1.2.4.    Market size and forecast, by Sales Channel

7.2.1.3.    Mexico

7.2.1.3.1.    Market size and forecast, by Drug Class
7.2.1.3.2.    Market size and forecast, by Indication
7.2.1.3.4.    Market size and forecast, by Sales Channel

7.2.2.    North America Autoimmune Disease Therapeutics Market size and forecast, by Drug Class
7.2.3.    North America Autoimmune Disease Therapeutics Market size and forecast, by Indication
7.2.4.    North America Autoimmune Disease Therapeutics Market size and forecast, by Sales Channel
7.2.5.    North America Autoimmune Disease Therapeutics Market size and forecast, by region

7.3.    Europe

7.3.1.    Key market trends and opportunities

7.3.1.1.    Germany

7.3.1.1.1.    Market size and forecast, by Drug Class
7.3.1.1.2.    Market size and forecast, by Indication
7.3.1.1.3.    Market size and forecast, by Sales Channel

7.3.1.2.    France

7.3.1.2.1.    Market size and forecast, by Drug Class
7.3.1.2.2.    Market size and forecast, by Indication
7.3.1.2.4.    Market size and forecast, by Sales Channel

7.3.1.3.    UK

7.3.1.3.1.    Market size and forecast, by Drug Class
7.3.1.3.2.    Market size and forecast, by Indication
7.3.1.3.4.    Market size and forecast, by Sales Channel

7.3.1.4.    Italy

7.3.1.4.1.    Market size and forecast, by Drug Class
7.3.1.4.2.    Market size and forecast, by Indication
7.3.1.4.4.    Market size and forecast, by Sales Channel

7.3.1.5.    Spain

7.3.1.5.1.    Market size and forecast, by Drug Class
7.3.1.5.2.    Market size and forecast, by Indication
7.3.1.5.3.    Market size and forecast, by Sales Channel

7.3.1.6.    Rest of Europe

7.3.1.6.1.    Market size and forecast, by Drug Class
7.3.1.6.2.    Market size and forecast, by Indication
7.3.1.6.3.    Market size and forecast, by Sales Channel

7.3.2.    Europe Autoimmune Disease Therapeutics Market size and forecast, by Drug Class
7.3.3.    Europe Autoimmune Disease Therapeutics Market size and forecast, by Indication
7.3.4.    Europe Autoimmune Disease Therapeutics Market size and forecast, by Sales Channel
7.3.5.    Europe Autoimmune Disease Therapeutics Market size and forecast, by region

7.4.    Asia-Pacific

7.4.1.    Key market trends and opportunities

7.4.1.1.    Japan

7.4.1.1.1.    Market size and forecast, by Drug Class
7.4.1.1.2.    Market size and forecast, by Indication
7.4.1.1.4.    Market size and forecast, by Sales Channel

7.4.1.2.    China

7.4.1.2.1.    Market size and forecast, by Drug Class
7.4.1.2.2.    Market size and forecast, by Indication
7.4.1.2.3.    Market size and forecast, by Sales Channel

7.4.1.3.    Australia

7.4.1.3.1.    Market size and forecast, by Drug Class
7.4.1.3.2.    Market size and forecast, by Indication
7.4.1.3.4.    Market size and forecast, by Sales Channel

7.4.1.4.    India

7.4.1.4.1.    Market size and forecast, by Drug Class
7.4.1.4.2.    Market size and forecast, by Indication
7.4.1.4.4.    Market size and forecast, by Sales Channel

7.4.1.5.    South Korea

7.4.1.5.1.    Market size and forecast, by Drug Class
7.4.1.5.2.    Market size and forecast, by Indication
7.4.1.5.3.    Market size and forecast, by Sales Channel

7.4.1.6.    Rest of Asia-Pacific

7.4.1.6.1.    Market size and forecast, by Drug Class
7.4.1.6.2.    Market size and forecast, by Indication
7.4.1.6.3.    Market size and forecast, by Sales Channel

7.4.2.    Asia-Pacific Autoimmune Disease Therapeutics Market size and forecast, by Drug Class
7.4.3.    Asia-Pacific Autoimmune Disease Therapeutics Market size and forecast, by Indication
7.4.5.    Asia-Pacific Autoimmune Disease Therapeutics Market size and forecast, by Sales Channel
7.4.6.    Asia-Pacific Autoimmune Disease Therapeutics Market size and forecast, by region

7.5.    LAMEA

7.5.1.    Key market trends and opportunities

7.5.1.1.    Brazil

7.5.1.1.1.    Market size and forecast, by Drug Class
7.5.1.1.2.    Market size and forecast, by Indication
7.5.1.1.4.    Market size and forecast, by Sales Channel

7.5.1.2.    Saudi Arabia

7.5.1.2.1.    Market size and forecast, by Drug Class
7.5.1.2.2.    Market size and forecast, by Indication
7.5.1.2.3.    Market size and forecast, by Sales Channel

7.5.1.3.    South Africa

7.5.1.3.1.    Market size and forecast, by Drug Class
7.5.1.3.2.    Market size and forecast, by Indication
7.5.1.3.4.    Market size and forecast, by Sales Channel

7.5.1.4.    Rest of LAMEA

7.5.1.4.1.    Market size and forecast, by Drug Class
7.5.1.4.2.    Market size and forecast, by Indication
7.5.1.4.3.    Market size and forecast, by Sales Channel

7.5.2.    LAMEA Autoimmune Disease Therapeutics Market size and forecast, by Drug Class
7.5.3.    LAMEA Autoimmune Disease Therapeutics Market size and forecast, by Indication
7.5.5.    LAMEA Autoimmune Disease Therapeutics Market size and forecast, by Sales Channel
7.5.6.    LAMEA Autoimmune Disease Therapeutics Market size and forecast, by region

CHAPTER 8:    COMPANY PROFILES

8.1.    Abbott Laboratories

8.1.1.    Company overview
8.1.2.    Company snapshot
8.1.3.    Operating business segments
8.1.4.    Product Portfolio
8.1.5.    Business performance

8.2.    AbbVie Inc.

8.2.1.    Company overview
8.2.2.    Company snapshot
8.2.3.    Operating business segments
8.2.4.    Product Portfolio
8.2.5.    Business performance
8.2.6.    Key strategic moves and developments

8.3.    Amgen Inc.

8.3.1.    Company overview
8.3.2.    Company snapshot
8.3.3.    Operating business segments
8.3.4.    Product portfolio
8.3.5.    Business performance
8.3.6.    Key strategic moves and developments

8.4.    AstraZeneca Plc.

8.4.1.    Company overview
8.4.2.    Company snapshot
8.4.3.    Operating business segments
8.4.4.    Product Portfolio
8.4.5.    Business performance

8.5.    Bristol-Myers Squibb Company

8.5.1.    Company overview
8.5.2.    Company snapshot
8.5.3.    Operating business segments
8.5.4.    Product portfolio
8.5.5.    Business performance
8.5.6.    Key strategic moves and developments

8.6.    F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)

8.6.1.    Company overview
8.6.2.    Company snapshot
8.6.3.    Operating business segments
8.6.4.    Product portfolio
8.6.5.    Business performance

8.7.    Johnson & Johnson

8.7.1.    Company overview
8.7.2.    Company snapshot
8.7.3.    Operating business segments
8.7.4.    Product Portfolio
8.7.5.    Business performance
8.7.6.    Key strategic moves and developments

8.8.    Novartis AG

8.8.1.    Company overview
8.8.2.    Company snapshot
8.8.3.    Operating business segments
8.8.4.    Product Portfolio
8.8.5.    Business performance

8.9.    Pfizer Inc.

8.9.1.    Company overview
8.9.2.    Company snapshot
8.9.3.    Operating business segments
8.9.4.    Product Portfolio
8.9.5.    Business performance
8.9.6.    Key strategic moves and developments

8.10.    UCB S.A.

8.10.1.    Company overview
8.10.2.    Company snapshot
8.10.3.    Product Portfolio
8.10.4.    Business performance
8.10.5.    Key strategic moves and developments

LIST OF TABLES

TABLE 01.    GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2017–2025 ($MILLION)
TABLE 02.    AUTOIMMUNE DISEASE THERAPEUTICS ANTI-INFLAMMATORY MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 03.    AUTOIMMUNE DISEASE THERAPEUTICS ANTIHYPERGLYCEMICS, BY REGION, 2017–2025 ($MILLION)
TABLE 04.    AUTOIMMUNE DISEASE THERAPEUTICS NSAIDS MARKET, 2017–2025 ($MILLION)
TABLE 05.    AUTOIMMUNE DISEASE THERAPEUTICS INTERFERONS MARKET, 2017–2025 ($MILLION)
TABLE 06.    AUTOIMMUNE DISEASE THERAPEUTICS OTHERS MARKET, 2017–2025 ($MILLION)
TABLE 07.    GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY INDICATION, 2017–2025 ($MILLION)
TABLE 08.    AUTOIMMUNE DISEASE THERAPEUTICS RHEUMATIC DISEASE MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 09.    AUTOIMMUNE DISEASE THERAPEUTICS TYPE 1 DIABETES, BY REGION, 2017–2025 ($MILLION)
TABLE 10.    AUTOIMMUNE DISEASE THERAPEUTICS MULTIPLE SCLEROSIS MARKET, 2017–2025 ($MILLION)
TABLE 11.    AUTOIMMUNE DISEASE THERAPEUTICS INFLAMMATORY BOWEL DISEASE MARKET, 2017–2025 ($MILLION)
TABLE 12.    AUTOIMMUNE DISEASE THERAPEUTICS OTHER INDICATIONS MARKET, 2017–2025 ($MILLION)
TABLE 13.    GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY SALES CHANNEL, 2017–2025 ($MILLION)
TABLE 14.    AUTOIMMUNE DISEASE THERAPEUTICS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2017–2025 ($MILLION)
TABLE 15.    AUTOIMMUNE DISEASE THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2017–2025 ($MILLION)
TABLE 16.    AUTOIMMUNE DISEASE THERAPEUTICS MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 2017–2025 ($MILLION)
TABLE 17.    GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY REGION, 2017-2025, ($MILLION)
TABLE 18.    US AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 19.    US AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 20.    US AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 21.    CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 22.    CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 23.    CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 24.    MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 25.    MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 26.    MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 27.    NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 28.    NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 29.    NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 30.    NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY REGION 2017-2025, ($MILLION)
TABLE 31.    GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 32.    GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 33.    GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 34.    FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 35.    FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 36.    FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 37.    UK AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 38.    UK AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 39.    UK AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 40.    ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 41.    ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 42.    ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 43.    SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 44.    SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 45.    SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 46.    REST OF EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 47.    REST OF EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 48.    REST OF EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 49.    EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 50.    EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 51.    EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 52.    EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY REGION 2017-2025, ($MILLION)
TABLE 53.    JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 54.    JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 55.    JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 56.    CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 57.    CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 58.    CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 59.    AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 60.    AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 61.    UK AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 62.    INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 63.    INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 64.    INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 65.    SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 66.    SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 67.    SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 68.    REST OF ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 69.    REST OF ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 70.    REST OF ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 71.    ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 72.    ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 73.    ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 74.    ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY REGION 2017-2025, ($MILLION)
TABLE 75.    BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 76.    BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 77.    BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 78.    SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 79.    SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 80.    SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 81.    SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 82.    SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 83.    SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 84.    REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 85.    REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 86.    REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 87.    LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2017-2025, ($MILLION)
TABLE 88.    LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2017-2025, ($MILLION)
TABLE 89.    LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY SALES CHANNEL 2017-2025, ($MILLION)
TABLE 90.    LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY REGION 2017-2025, ($MILLION)
TABLE 91.    ABBOTT: COMPANY SNAPSHOT
TABLE 92.    ABBOTT: OPERATING SEGMENTS
TABLE 93.    ABBOTT: PRODUCT PORTFOLIO
TABLE 94.    ABBVIE: COMPANY SNAPSHOT
TABLE 95.    ABBVIE: OPERATING SEGMENTS
TABLE 96.    ABBOTT: PRODUCT PORTFOLIO
TABLE 97.    AMGEN: COMPANY SNAPSHOT
TABLE 98.    AMGEN: PRODUCT PORTFOLIO
TABLE 99.    ASTRAZENECA: COMPANY SNAPSHOT
TABLE 100.    ASTRAZENECA: OPERATING SEGMENTS
TABLE 101.    ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 102.    BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 103.    BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 104.    ROCHE: COMPANY SNAPSHOT
TABLE 105.    ROCHE: OPERATING SEGMENTS
TABLE 106.    ROCHE: PRODUCT PORTFOLIO
TABLE 107.    J&J: COMPANY SNAPSHOT
TABLE 108.    J&J: OPERATING SEGMENTS
TABLE 109.    J&J: PRODUCT PORTFOLIO
TABLE 110.    NOVARTIS: COMPANY SNAPSHOT
TABLE 111.    NOVARTIS: OPERATING SEGMENTS
TABLE 112.    NOVARTIS: PRODUCT PORTFOLIO
TABLE 113.    PFIZER: COMPANY SNAPSHOT
TABLE 114.    PFIZER: OPERATING SEGMENTS
TABLE 115.    PFIZER: PRODUCT PORTFOLIO
TABLE 116.    UCB: COMPANY SNAPSHOT
Table 117.    UCB: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.    GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SEGMENTATION
FIGURE 02.    TOP INVESTMENT POCKETS
FIGURE 03.    GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET DYNAMICS
FIGURE 04.    TOP PLAYER POSITIONNG, 2017
FIGURE 05.    COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS ANTI-INFLAMMATORY MARKET, 2017 AND 2025 ($MILLION)
FIGURE 06.    COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS ANTIHYPERGLYCEMICS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 07.    COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS NSAIDS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 08.    COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS INTERFERONS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 09.    COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS OTHERS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 10.    COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS RHEUMATIC DISEASE MARKET, 2017 AND 2025 ($MILLION)
FIGURE 11.    COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS TYPE 1 DIABETES MARKET, 2017 AND 2025 ($MILLION)
FIGURE 12.    COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS MULTIPLE SCLEROSIS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 13.    COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS INFLAMMATORY BOWEL DISEASE MARKET, 2017 AND 2025 ($MILLION)
FIGURE 14.    COMPARATIVE COUNTRY ANALYSIS OF AUTOIMMUNE DISEASE THERAPEUTICS OTHER INDICATIONS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 15.    COMPARATIVE COUNTRY ANALYSIS AUTOIMMUNE DISEASE THERAPEUTICS MARKET FOR HOSPITAL PHARMACY, 2017 AND 2025 ($MILLION)
FIGURE 16.    COMPARATIVE COUNTRY ANALYSIS AUTOIMMUNE DISEASE THERAPEUTICS MARKET FOR ONLINE PROVIDERS, 2017 AND 2025 ($MILLION)
FIGURE 17.    COMPARATIVE COUNTRY ANALYSIS AUTOIMMUNE DISEASE THERAPEUTICS MARKET FOR DRUG STORES & RETAIL PHARMACIES, 2017 AND 2025 ($MILLION)
FIGURE 18.    ABBOTT: NET SALES, 2015–2017 ($MILLION)
FIGURE 19.    ABBOTT: NET SALES SHARE BY OPERATING SEGMENT, 2017 (%)
FIGURE 20.    ABBOTT: NET SALES SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 21.    ABBVIE: NET SALES, 2015–2017 ($MILLION)
FIGURE 22.    ABBVIE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 23.    ABBVIE: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 24.    AMGEN: NET SALES, 2015–2017 ($MILLION)
FIGURE 25.    AMGEN: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 26.    AMGEN: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 27.    ASTRAZENECA: REVENUE, 2015–2017 ($MILLION)
FIGURE 28.    ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 29.    REVENUE, 2015–2017 ($MILLION)
FIGURE 30.    BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 31.    ROCHE: NET SALES, 2015–2017 ($MILLION)
FIGURE 32.    ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 33.    ROCHE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 34.    J&J: REVENUE, 2015–2017 ($MILLION)
FIGURE 35.    J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 36.    J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 37.    NET SALES, 2015–2017 ($MILLION)
FIGURE 38.    NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 39.    NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 40.    PFIZER: REVENUE, 2015–2017 ($MILLION)
FIGURE 41.    PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 42.    PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 43.    UCB: NET SALES, 2015–2017 ($MILLION)
FIGURE 44.    UCB: REVENUE SHARE by geography, 2017 (%)

 
 

Autoimmune disease is a condition in which the immune system mistakenly attacks own body cells. Drugs such as anti-inflammatory, NSAIDs, interferons, immune suppressants, corticosteroids, beta-blockers, are widely used for treatment & management of autoimmune disease. The adoption of autoimmune disease therapeutics is expected to increase owing to increase in prevalence of autoimmune diseases across the globe, rise in adoption of advanced therapeutics along with wide availability of drugs.

Increase in R&D studies for the development of ideal therapeutics, expected launch of pipeline drugs, technological advancement in screening procedures are projected to supplement the market growth during the forecast period. Moreover, rise in number of risk factors such as sedentary lifestyle pattern, & obesity is further expected to fuel the market growth. However, higher cost of advanced therapeutics can hinder the market growth.

North America is a major revenue contributing region and is expected to remain dominant during the forecast period due to surge in use as well as easy availability of therapeutics, early screening of the disease, favorable reimbursement policies, strong presence of key players, and higher number of target population.

In addition, Asia-Pacific and LAMEA are expected to offer lucrative growth opportunities to the key players during the forecast period due to increase in prevalence of autoimmune disease, rise in healthcare awareness, improvement in healthcare infrastructure with developing economies, and growth in the demand for advanced therapeutics.  

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

Download Sample

OR

Purchase Full Report of
Autoimmune Disease Therapeutics Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample

Buy Full Version
"Autoimmune Disease Therapeutics Market"
Purchase Enquiry